{"id":420825,"date":"2026-04-28T00:37:09","date_gmt":"2026-04-28T00:37:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/420825\/"},"modified":"2026-04-28T00:37:09","modified_gmt":"2026-04-28T00:37:09","slug":"broken-pbs-system-behind-failure-to-list-mounjaro-for-type-2-diabetics-according-to-medicines-australia","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/420825\/","title":{"rendered":"Broken PBS system behind failure to list Mounjaro for type 2 diabetics, according to Medicines Australia"},"content":{"rendered":"<p class=\"paragraph_paragraph___QITb\">Hundreds of thousands of Australians with diabetes will continue paying thousands of dollars a year for lifesaving medication not on the Pharmaceutical Benefits Scheme, because of the &#8220;broken&#8221; process behind subsidising medicines, according to the peak industry body.\u00a0<\/p>\n<p class=\"paragraph_paragraph___QITb\">The Pharmaceutical Benefits Advisory Committee (PBAC) recommended tirzepatide \u2014 an injectable GLP-1 medication sold as Mounjaro \u2014 be subsidised for adults with &#8220;inadequately controlled&#8221; type 2 diabetes.<\/p>\n<p class=\"paragraph_paragraph___QITb\">But after a protracted stand-off with the federal government, the drug&#8217;s manufacturer Eli Lilly declared it would not proceed with the PBS process, airing a cluster of grievances including that the price Australia was willing to pay for the drug was too low.<\/p>\n<p class=\"paragraph_paragraph___QITb\">The company estimated 450,000 Australians with type 2 diabetes would miss out on discounted medication as a result, in what Medicines Australia CEO Liz de Somer said was a very disappointing outcome.<\/p>\n<p><a href=\"https:\/\/www.abc.net.au\/news\/2025-08-07\/pbs-waitlist-times-medication-trump-tariff\/105618370\" data-component=\"FullBleedLink\" class=\"RelatedCard_link__rsgR9 FullBleedLink_root__lTw_U interactive_focusContext__yRhc_ interactive_defaults__AKxUU FullBleedLink_showVisited__g3Xvz\" rel=\"nofollow noopener\" target=\"_blank\">Lengthy PBS delays a bigger issue than Trump&#8217;s tariffs, according to peak body<\/a><\/p>\n<p class=\"Typography_base__sj2RP RelatedCard_synopsis__cFwMW Typography_sizeMobile14__u7TGe Typography_lineHeightMobile20___U7Vr Typography_regular__WeIG6 Typography_colourInherit__dfnUx\" data-component=\"Typography\">The federal government is working to shield Australia from Donald Trump&#8217;s potential tariffs, but the peak pharmaceutical industry body argues there&#8217;s a bigger issue closer to home.<\/p>\n<p>&#8220;I think the real issue that&#8217;s being raised here are issues that have been widely discussed for several years now \u2014 the system in Australia is broken,&#8221;  Ms de Somer said.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;It&#8217;s not keeping pace with innovation. It&#8217;s not recognising the value of innovation.&#8221;<\/p>\n<p class=\"paragraph_paragraph___QITb\">When drugs are placed on the PBS, patients are able to receive medicines at a small portion of the cost \u2014 currently $25, or $7.70 for concession card holders.<\/p>\n<p class=\"paragraph_paragraph___QITb\">But patients, advocacy groups and pharmaceutical companies have long argued the path leading up to the PBS listing is overly complex, involves excessive red tape and takes too long, with a median time of 22 months for a new medicine to land on the scheme once it is approved by the regulator.<\/p>\n<p class=\"paragraph_paragraph___QITb\">Those issues have been <a class=\"Link_link__kR0xA Link_link__5eL5m ScreenReaderOnly_srLinkHint__OysWz Link_showVisited__C1Fea Link_showFocus__ALyv2\" href=\"https:\/\/www.abc.net.au\/news\/2025-03-19\/australia-defends-pbs-us-pharma-urges-reciprocal-tariffs\/105072750\" data-component=\"Link\" data-uri=\"coremedia:\/\/article\/105072750\" rel=\"nofollow noopener\" target=\"_blank\">a long-held frustration of US pharmaceutical companies<\/a>, which also argue the scheme&#8217;s pricing process undervalues innovation and threatens billions of dollars in lost sales.<\/p>\n<p><img decoding=\"async\" alt=\"Elizabeth de Somer, CEO of Medicines Australia\" class=\"Image_image__5tFYM ContentImage_image__DQ_cq\"  src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/04\/68a12b80a5310f7dc58305851733b30a.jpeg\" loading=\"lazy\" data-component=\"Image\" data-lazy=\"true\"\/><\/p>\n<p class=\"Typography_base__sj2RP FigureCaption_text__zDxQ5 Typography_sizeMobile12__w_FPC Typography_lineHeightMobile20___U7Vr Typography_regular__WeIG6 Typography_colourInherit__dfnUx\" data-component=\"Typography\">Medicines Australia CEO Liz de Somer said the latest stalemate over Mounjaro highlighted the need for more urgent action. (Supplied: UNSW Media)<\/p>\n<p class=\"paragraph_paragraph___QITb\">The <a class=\"Link_link__kR0xA Link_link__5eL5m ScreenReaderOnly_srLinkHint__OysWz Link_showVisited__C1Fea Link_showFocus__ALyv2\" href=\"https:\/\/www.abc.net.au\/news\/2024-09-11\/proposal-to-speed-up-medicine-approvals\/104338766\" data-component=\"Link\" data-uri=\"coremedia:\/\/article\/104338766\" rel=\"nofollow noopener\" target=\"_blank\">first complete review of the system in three decades<\/a> was handed to the federal government in 2024, making several recommendations aimed at streamlining processes so people could access subsidised medicines earlier.<\/p>\n<p class=\"paragraph_paragraph___QITb\">An advisory group is guiding the government&#8217;s response to the so-called Health Technology Assessment (HTA) review, but Ms de Somer said the latest stalemate over Mounjaro highlighted the need for more urgent action.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;The government has recognised that there&#8217;s an issue. Stakeholders, patients, patient groups, and their families and communities have recognised there&#8217;s a problem here,&#8221; she said.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;It&#8217;s now a time to act, and we&#8217;re ready and waiting.&#8221;<\/p>\n<p>Patients forced to ration Mounjaro due to expense<\/p>\n<p class=\"paragraph_paragraph___QITb\">Ingrid Baas-Becking is a double diabetic, meaning she has type 1 and type 2 diabetes, and has to pay almost $700 every two months for 15 milligrams of Mounjaro.<\/p>\n<p class=\"paragraph_paragraph___QITb\">This puts immense financial strain on the 74-year-old who relies on the pension.<\/p>\n<p><img decoding=\"async\" alt=\"A woman with white hair stands in a garden\" class=\"Image_image__5tFYM ContentImage_image__DQ_cq\"  src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/04\/ba753a411bd565261933ac4e467e5dba.jpeg\" loading=\"lazy\" data-component=\"Image\" data-lazy=\"true\"\/><\/p>\n<p class=\"Typography_base__sj2RP FigureCaption_text__zDxQ5 Typography_sizeMobile12__w_FPC Typography_lineHeightMobile20___U7Vr Typography_regular__WeIG6 Typography_colourInherit__dfnUx\" data-component=\"Typography\">Ingrid Baas-Becking said her health had improved immensely since starting Mounjaro. (Supplied: Ingrid Baas-Becking)<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;I&#8217;m doing without other things to afford the Mounjaro \u2026 I can&#8217;t do anything other than buy the Mounjaro.&#8221;<\/p>\n<p class=\"paragraph_paragraph___QITb\">Mounjaro is a unique type of GLP-1 drug because it also mimics the GIP hormone to improve insulin sensitivity and decrease appetite.<\/p>\n<p class=\"paragraph_paragraph___QITb\">Since starting Mounjaro this year Ms Baas-Becking has seen major improvements to her health, which she did not experience when she tried other GLP-1 drugs.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;I&#8217;m losing weight for the first time in my life and I&#8217;m using about 50 per cent less insulin.&#8221;<\/p>\n<p class=\"paragraph_paragraph___QITb\">But Ms Baas-Becking said she was rationing the drug because she could not afford a higher dose.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;I&#8217;m counting the clicks [of the injectable pen]. I&#8217;m taking half the dose because if I used the full dose I would be buying it every month, not every two months.&#8221;<\/p>\n<p class=\"paragraph_paragraph___QITb\">She said it was, &#8220;disappointing&#8221; Mounjaro still wasn&#8217;t going to be added to the PBS and the announcement &#8220;lowered the reputation&#8221; of Eli Lilly in her opinion.<\/p>\n<p>Keeping PBS prices low comes with trade-offs: health economist<\/p>\n<p class=\"paragraph_paragraph___QITb\">Once the PBAC recommends a medication be listed on the PBS, the government negotiates with the pharmaceutical company to strike a commercial agreement that aims to protect taxpayers by mitigating risks, like uncertainty around the overall cost to the PBS.<\/p>\n<p class=\"paragraph_paragraph___QITb\">Under one type of agreement, if the drug is prescribed to more people than anticipated, the pharmaceutical company will share the additional cost with the government.<\/p>\n<p><img decoding=\"async\" alt=\"A box of\u00a0Mounjaro, a drug used for treating type 2 diabetes, sitting on a counter\" class=\"Image_image__5tFYM ContentImage_image__DQ_cq\"  src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/04\/fd0e5b28054db22d295b3472acb142e9.jpeg\" loading=\"lazy\" data-component=\"Image\" data-lazy=\"true\"\/><\/p>\n<p class=\"Typography_base__sj2RP FigureCaption_text__zDxQ5 Typography_sizeMobile12__w_FPC Typography_lineHeightMobile20___U7Vr Typography_regular__WeIG6 Typography_colourInherit__dfnUx\" data-component=\"Typography\">Mounjaro, a tirzepatide injection drug, is used for treating type 2 diabetes. (Reuters:\u00a0George Frey)<\/p>\n<p class=\"paragraph_paragraph___QITb\">Manny Simons, general manager of Lilly Australia and New Zealand, said this presented a &#8220;disproportionate financial risk to Lilly&#8221;.<\/p>\n<p>&#8220;Our decision was driven by the simple reality that the price conditions proposed by the Australian government are unrealistic and unviable,&#8221;  Mr Simons said.<\/p>\n<p class=\"paragraph_paragraph___QITb\">Health economist at the University of Melbourne&#8217;s Centre for Health Policy, Philip Clarke, said it was unclear whether Eli Lilly was bluffing just to get a better deal.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;It is hard to judge the financial costs and risk to Eli Lilly as the prices the government actually pays for new drugs are often not disclosed,&#8221; he said.<\/p>\n<p class=\"paragraph_paragraph___QITb\">Professor Clarke said the government&#8217;s commitment to keeping the prices of PBS medication low can could with trade-offs and meant not every drug would be listed, especially when there were alternatives.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;If you go into a shop and want to buy every car you&#8217;re not going to get a good deal,&#8221; he said.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;It&#8217;s important to recognise that in the current constrained budget environment, the more taxpayers spend on one drug, like Mounjaro, often the less funding is available for other medicines.&#8221;<\/p>\n<p class=\"paragraph_paragraph___QITb\">Health Minister Mark Butler said he had asked his department for advice about the negotiations with Eli Lilly.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;There are often very robust price negotiations between big multinational drug companies and the federal government, the officials that we ask to do that work for us,&#8221; Mr Butler said on Sunday.<\/p>\n<p class=\"paragraph_paragraph___QITb\">&#8220;That tension really and that price negotiation is a very big reason why we have such a successful and sustainable Pharmaceutical Benefits Scheme.&#8221;<\/p>\n<p class=\"paragraph_paragraph___QITb\">Semaglutide, which is sold under the brand name Ozempic, is already listed on the PBS for people with type 2 diabetes and Wegovy, with the same active ingredient, has been recommended for PBS listing.<\/p>\n<p>Loading&#8230;<\/p>\n","protected":false},"excerpt":{"rendered":"Hundreds of thousands of Australians with diabetes will continue paying thousands of dollars a year for lifesaving medication&hellip;\n","protected":false},"author":2,"featured_media":420826,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[1702,103,61,60,339,371,1357,11495,96307,114510],"class_list":{"0":"post-420825","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-diabetes","9":"tag-health","10":"tag-ie","11":"tag-ireland","12":"tag-medical","13":"tag-medication","14":"tag-medicine","15":"tag-mounjaro","16":"tag-pbs","17":"tag-pharmaceutical-benefits-scheme"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/420825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=420825"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/420825\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/420826"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=420825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=420825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=420825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}